Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-invasive imaging of atherosclerosis progression and cardiovascular outcome: a systematic review and meta-analysis.

The international journal of cardiovascular imaging·2026
Same author

NOD1 is a key mediator of atrial myopathy in heart failure.

Theranostics·2026
Same author

Low-dose Empagliflozin Does Not Modify Myocardial Energetics and Function in a Large-animal Model of Hibernating Myocardium.

Journal of cardiovascular translational research·2026
Same author

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study.

JACC. CardioOncology·2026
Same author

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.

The American journal of clinical nutrition·2026
Same author

Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period.

GeroScience·2026

Related Experiment Video

Updated: Jul 13, 2026

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

53.1K

Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement.

Frederick G P Welt1, Wayne Batchelor2, J Richard Spears3

  • 1Department of Medicine, Division of Cardiovascular Medicine, University of Utah Hospital, Salt Lake City, Utah, USA.

Journal of the American College of Cardiology
|May 29, 2024
PubMed
Summary

Myocardial ischemia-reperfusion injury, a complication of ST-elevation myocardial infarction treatment, causes further heart damage. Understanding its molecular basis aids in developing new pharmacologic and mechanical therapies to improve patient outcomes.

Keywords:
STEMIinflammationischemiareperfusion

More Related Videos

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice
08:28

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice

Published on: January 19, 2022

6.6K
Model of Ischemia and Reperfusion Injury in Rabbits
06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

1.2K

Related Experiment Videos

Last Updated: Jul 13, 2026

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

53.1K
Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice
08:28

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice

Published on: January 19, 2022

6.6K
Model of Ischemia and Reperfusion Injury in Rabbits
06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

1.2K

Area of Science:

  • Cardiology
  • Pathophysiology
  • Biomedical Engineering

Background:

  • ST-segment elevation myocardial infarction (STEMI) treatment has improved, yet patient mortality remains high.
  • Reperfusion therapy, while crucial for myocardial salvage, can paradoxically exacerbate injury through ischemia-reperfusion (I-R) processes.
  • Myocardial ischemia-reperfusion injury is a significant clinical challenge following acute myocardial infarction.

Purpose of the Study:

  • To review the pathological and molecular mechanisms underlying myocardial ischemia-reperfusion injury.
  • To explore current and emerging therapeutic strategies for mitigating I-R injury.
  • To highlight the potential of both pharmacologic and mechanical interventions.

Main Methods:

  • Review of existing literature on myocardial ischemia-reperfusion injury.
  • Analysis of molecular pathways including reactive oxygen species, inflammation, calcium overload, endothelial dysfunction, and microvascular impairment.
  • Examination of preclinical and clinical data for pharmacologic and mechanical therapeutic approaches.

Main Results:

  • Pathologic and molecular bases of I-R injury are increasingly understood.
  • Pharmacologic strategies have shown promise in preclinical models and some clinical settings.
  • Mechanical approaches, such as cardiac unloading, are under investigation in clinical trials.

Conclusions:

  • Myocardial ischemia-reperfusion injury involves complex molecular and cellular processes.
  • Targeting these mechanisms offers therapeutic opportunities.
  • Combined pharmacologic and mechanical strategies may represent the future of I-R injury management in STEMI.